Policy Blog

This week, Medicaid dominated the policy agenda as new analyses put a $664 billion price tag on federal spending reductions and states began grappling with implementation costs under the One Big Beautiful Bill Act. At FDA, Vinay Prasad’s second departure raised fresh questions about Commissioner Makary’s leadership and the agency’s regulatory direction. And an AI buildout continued across payers, providers, and federal agencies—including a high-profile ban on Anthropic’s Claude at HHS.